Contract manufacturing expansion Cherokee is expanding its core contract development and manufacturing services to emerging and legacy pharmaceutical companies, presenting opportunities to upsell CDMO capabilities to firms seeking scalable API development and production.

FDA compliance strength With a stellar FDA track record and only two minor CDER observations in nine years, Cherokee can reassure potential clients about quality, regulatory readiness, and expedited approval support for complex chemistries.

Legacy facility advantage The Riverside and associated 323 acre site, formerly Merck’s, combined with its developed fermentation and multi-step chemistry capabilities, positions Cherokee to handle large-scale, complex manufacturing programs that require robust containment and scale-up.

Strategic partnership potential Maintaining a strong relationship with Merck and being a minority-owned, self-managed team-driven organization signals reliability, preferred supplier potential, and flexible collaboration models for large pharma and biotech customers.

Technology and capacity fit Active use of modern tech stack and scalable process development capabilities align with digitalized CDMO operations, enabling efficient project management, rapid prototyping, and rapid scale for clients moving from concept to commercial quantities.